Global Primary Immunodeficiency Market, By Product (Immunoglobulin Therapy, Antibiotics, Others), End-Users (Hospitals, Clinics, Others) – Industry Trends and Forecast to 2030.
Primary Immunodeficiency Market Analysis and Size
Primary immunodeficiencies are defined as the disorders in which part of the body's immune system is missing or does not function normally. Immune deficiencies can result in persistent or auto-inflammatory disorders, recurring infections, tumours, and disorders of various organs. Rise in the government awareness programs about the disease will uplift the market growth.
Data Bridge Market Research analyses that the primary immunodeficiency market which was USD 7.8 billion in 2022, would rocket up to USD 12.9 billion by 2030, and is expected to undergo a CAGR of 6.5% during the forecast period. “Immunoglobulin therapy” dominates the treatment segment of the primary immunodeficiency market owing to their therapeutic efficacy and minimal side effects. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Primary Immunodeficiency Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Product (Immunoglobulin Therapy, Antibiotics, Others), End-Users (Hospitals, Clinics, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Baxter international Inc (U.S.), Takeda Pharmaceutical Company Limited (Japan), CSL Ltd (Australia), Octapharma AG (Switzerland), Biotest AG (Germany), Kedrion Biopharma Inc (Italy), Bio Products Laboratory Limited (U.K.), LFB group (France) Grifols S.A (Spain), and Lupin Pharmaceuticals (India)
|
|
Market Opportunities
|
|
Market Definition
Primary immunodeficiency refers to a group of inherited disorders characterized by defects in the immune system's ability to effectively fight off infections. These disorders result from genetic abnormalities that impair the production or function of immune cells or proteins. Symptoms can include recurrent infections, severe or unusual infections, poor response to treatment, and autoimmune diseases. Diagnosis typically involves genetic testing and management often includes immunoglobulin replacement therapy, antibiotics, and other targeted treatments.
Primary Immunodeficiency Market Dynamics
Drivers
- Increasing Prevalence of Immunodeficiency Disorders
The rising prevalence of immunodeficiency disorders worldwide is a significant driver for the market. Factors such as genetic predisposition, environmental triggers, and improved diagnostic capabilities contribute to the identification of more cases, driving the demand for diagnostic tests, therapies, and supportive care.
- Technological Advancements in Diagnostics and Therapeutics
Advances in diagnostic technologies, including genetic testing, flow cytometry, and next-generation sequencing, enable more accurate and early detection of immunodeficiency disorders. Similarly, the development of targeted therapies, gene therapies, and biologics provides innovative treatment options, improving patient outcomes and driving market growth.
Opportunities
- Advances in Treatment Options
The continuous advancements in the understanding of immunodeficiency disorders and the development of targeted therapies create opportunities for innovative treatment options. There is a growing focus on gene therapies, biologics, and immunomodulatory drugs, which could significantly impact the immunodeficiency market.
- Increasing Awareness and Diagnosis
Improved awareness about immunodeficiency disorders among healthcare professionals and the general population can lead to earlier and more accurate diagnosis. This increased awareness can drive the demand for diagnostic tests, screening programs, and early intervention, presenting opportunities for companies involved in diagnostic technologies and services.
Restraint/Challenge
- High Treatment Costs
The cost of treatments for immunodeficiency disorders, such as immunoglobulin replacement therapy and targeted biologics, can be substantial. This can create financial barriers to access for patients and healthcare systems, limiting the adoption of advanced therapies.
This primary immunodeficiency market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the primary immunodeficiency market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Primary immunodeficiency Market Scope
The primary immunodeficiency market is segmented on the basis of product and end-users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Immunoglobulin Therapy
- Antibiotics
- Others
End-Users
- Hospitals
- Clinics
- Others
Primary immunodeficiency Market Regional Analysis/Insights
The primary immunodeficiency market is analysed and market size insights and trends are provided by country, product, and end-users, as referenced above.
The countries covered in the primary immunodeficiency market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is expected to dominate the primary immunodeficiency market because of the presence of major market players and availability of advanced medications for the treatment within the region.
Asia-Pacific is expected to witness the fastest growth during the forecast period of 2022-2030 because of the continuous healthcare developments in developing countries such as India and China.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The primary immunodeficiency market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for primary immunodeficiency market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the primary immunodeficiency market. The data is available for historic period 2015-2020.
Competitive Landscape and Primary immunodeficiency Market Share Analysis
The Primary immunodeficiency Market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the primary immunodeficiency market are:
- Baxter international Inc (U.S.)
- Takeda Pharmaceutical Company Limited (Japan)
- CSL Ltd (Australia)
- Octapharma AG (Switzerland)
- Biotest AG (Germany)
- Kedrion Biopharma Inc (Italy)
- Bio Products Laboratory Limited (U.K.)
- LFB group (France)
- Grifols S.A (Spain)
- Lupin Pharmaceuticals (India)
SKU-